Study on heart and kidney health in type 2 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have type 2 diabetes.
- You are currently taking or need to start treatment with enavogliflozin, dapagliflozin, or empagliflozin.
- You do not have severe liver disease.
- Your kidneys are working well enough (eGFR at least 60).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.